Trinity Biotech Reports Perceptive Advisors Plans Debt-to-Equity Conversion to Strengthen Balance Sheet

Trinity Biotech is considering a proposal from its largest investor and primary lender, Perceptive Advisors, to convert a portion of its outstanding debt into equity. This strategic move aims to strengthen the company's balance sheet, improve financial flexibility, and support its growth objectives amid ongoing financial challenges, including declining revenue and profitability. Trinity Biotech operates in the healthcare sector, focusing on clinical diagnostics and diabetes management solutions, with a portfolio that includes wearable biosensors. Perceptive Advisors, a leading life sciences investment firm, has been a supportive partner throughout the company's recent transformation. The company expresses optimism about engaging in discussions that align with the interests of all stakeholders. Forward-looking statements caution that the proposed equitization is subject to customary risks and uncertainties.